Fig. 6

Forest Plots of Type I CD4 and CD8 Ag-specific T Cell Immunity (N = 27) at 6 weeks and at 3 months. Evidence of type I CD4+ and CD8+ antigen-specific T cell immunity against shared melanoma antigens, including lineage antigens (MART-1, gp-100) and cancer testis antigen (NY-ESO1), in the absence of prior vaccination. These responses were boosted after ipilimumab at a 6 weeks and b 3 months